Anxiety Disorders And Depression Treatment Market Summary

The global anxiety disorders and depression treatment market size was estimated at USD 15.42 billion in 2024 and is projected to reach USD 19.28 billion by 2030, growing at a CAGR of 3.8% from 2025 to 2030. This steady growth reflects the rising prevalence of mental health conditions worldwide, driven by lifestyle changes, increased stress levels, and greater recognition of mental well-being as a public health priority. Collaboration among pharmaceutical companies, non-governmental organizations (NGOs), and mental health organizations has played a critical role in raising public awareness and reducing the stigma associated with mental health issues, thereby improving diagnosis and treatment rates.

This cultural shift encourages individuals to seek professional help at earlier stages, which in turn drives demand for effective and long-term treatment solutions. Increased openness about mental health has also supported the adoption of both pharmacological and non-pharmacological therapies. Moreover, government initiatives and funding are bolstering mental health research and treatment programs worldwide, ensuring that sufficient resources are dedicated to developing, approving, and refining therapeutic options for anxiety and depression, as well as improving access to care across diverse populations.

Key Market Trends & Insights

• In terms of region, North America was the largest revenue generating market in 2024. This dominance can be attributed to advanced healthcare infrastructure, high awareness levels, favorable reimbursement policies, and strong presence of key pharmaceutical players actively investing in mental health drug development.
• Country-wise, U.S. is expected to register the significant CAGR from 2025 to 2030. Factors such as increasing diagnosis rates, rising healthcare expenditure, supportive regulatory frameworks, and growing acceptance of mental health treatments are expected to contribute to this accelerated growth.
• By drug type, the antidepressants segment accounted for the highest revenue share of 32.4% in 2024. The widespread prescription of antidepressants, their proven clinical efficacy, and continuous advancements in drug formulations have supported their strong market position.
• By indication, the anxiety segment led the market with a revenue share of 55.4% in 2024. The high prevalence of anxiety disorders, combined with increased awareness and improved screening methods, has significantly contributed to the dominance of this segment.

Order a free sample PDF of the Anxiety Disorders And Depression Treatment Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 15.42 Billion
• 2030 Projected Market Size: USD 19.28 Billion
• CAGR (2025-2030): 3.8%
• North America: Largest market in 2024

Key Companies & Market Share Insights

Some major companies in the market are Pfizer Inc.; H. Lundbeck A/S; GSK plc; Merck & Co., Inc.; Eli Lilly and Company. Companies in this market focus on offering mental health treatments with drugs and other therapies. The companies also aim to grow by increasing new drug approvals and improving their distribution networks.

• PRISTIQ (desvenlafaxine) is an SNRI proven effective for major depressive disorder, supported by Phase 4 studies using the HAM-D17 scale. Pfizer actively researches mental health, promotes awareness, and integrates effective treatments into healthcare systems for managing anxiety and depression.
• Lundbeck A/S is involved in researching, developing, producing, promoting, and selling pharmaceutical products worldwide. The company focuses on products designed for brain disorders such as depression, schizophrenia, Alzheimer’s, Parkinson’s, and migraines.

Key Players

• Pfizer Inc.
• Lundbeck A/S
• GSK plc
• Merck & Co., Inc.
• Eli Lilly and Company
• AstraZeneca
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.
• AbbVie Inc.
• Sanofi

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The anxiety disorders and depression treatment market is witnessing consistent growth due to increasing awareness, supportive government initiatives, and advancements in therapeutic options. Strong collaboration among stakeholders continues to reduce stigma and improve treatment-seeking behavior globally. North America, particularly the U.S., remains a key growth driver due to its robust healthcare ecosystem and high adoption of mental health treatments. The dominance of antidepressants and the anxiety indication highlights ongoing demand for effective pharmacological solutions. Overall, sustained investments in research, policy support, and public awareness are expected to further strengthen market expansion through 2030.